SAB BIOTHERAPEUTICS, INC. (SABS) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 11.71M USD | Liabilities, Current |
| Cash and equivalents | 8.27M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.71M | $8.27M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $9.85M | $20.52M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $10.68M | $10.50M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $10.79M | $29.42M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $10.68M | $3.69M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $9.65M | $5.64M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $7.98M | $8.90M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $8.82M | $9.17M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $7.55M | $17.24M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $8.30M | $14.03M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $10.81M | $56.57M | (m) | $0.00 | (m) | (m) |
| 2023-09-30 | (m) | $9.21M | $2.43M | (m) | $0.00 | (m) | (m) |
| 2023-06-30 | (m) | $11.01M | $7.77M | (m) | $364.12K | (m) | (m) |
| 2023-03-31 | (m) | $13.67M | $13.06M | (m) | $763.12K | (m) | (m) |
| 2022-12-31 | (m) | $14.99M | $15.05M | (m) | $5.56M | (m) | (m) |
| 2022-09-30 | (m) | $17.10M | $8.33M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $16.14M | $16.62M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $18.26M | $22.41M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $24.68M | $33.21M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $322.38K | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $152.88K | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $80.00K | (m) | (m) | (m) | (m) | (m) |
| 2021-01-14 | (m) | $267.54K | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $306.20K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |